Clinical trial
Study of XIAP Antisense for Advanced Cancers
NCT00385775 · Aegera Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00385775 |
|---|---|
| Title | Study of XIAP Antisense for Advanced Cancers |
| Official title | A Phase I Trial of AEG35156 Administered by 2-Hour Intravenous Infusion in Patients With Advanced Cancers |
| Lead sponsor | Aegera Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancer |
| Intervention type | Drug |
| Interventions | AEG35156 |
| Enrollment | 30 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Oct 11, 2006 |
| Last update posted | Aug 21, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: